Survival with AGS-003, an autologous dendritic cell–based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results

BACKGROUND: AGS-003 is an autologous immunotherapy prepared from fully matured and optimized monocyte-derived dendritic cells, which are co-electroporated with amplified tumor RNA plus synthetic CD40L RNA. AGS-003 was evaluated in combination with sunitinib in an open label phase 2 study in intermed...

Descripción completa

Detalles Bibliográficos
Autores principales: Amin, Asim, Dudek, Arkadiusz Z, Logan, Theodore F, Lance, Raymond S, Holzbeierlein, Jeffrey M, Knox, Jennifer J, Master, Viraj A, Pal, Sumanta K, Miller, Wilson H, Karsh, Lawrence I, Tcherepanova, Irina Y, DeBenedette, Mark A, Williams, W Lee, Plessinger, Douglas C, Nicolette, Charles A, Figlin, Robert A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4404644/
https://www.ncbi.nlm.nih.gov/pubmed/25901286
http://dx.doi.org/10.1186/s40425-015-0055-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4404644/
https://www.ncbi.nlm.nih.gov/pubmed/25901286
http://dx.doi.org/10.1186/s40425-015-0055-3

Ejemplares similares